Growth of preschool age children receiving daily inhaled corticosteroids.

Inhaled Corticosteroids and Preschool Growth: Navigating the Desert of Asthma Management

Inhaled corticosteroids (ICS) are a cornerstone of asthma treatment, but their potential impact on child growth remains a concern. This study investigates the effects of ICS use on linear growth in preschool children with asthma, comparing the growth trajectories of children receiving ICS with those receiving oral montelukast. The researchers aim to provide evidence-based guidance on the use of ICS in this vulnerable population, ensuring optimal asthma management without compromising growth.

ICS Use and Preschool Growth: A Balanced Approach

The study found that low-to-medium doses of ICS administered through a valved holding chamber were not associated with growth inhibition in preschool children with asthma. However, the study identified a small but statistically significant decrease in growth in female subjects with positive skin testing to inhalant allergens and in subjects receiving intranasal corticosteroids.

Balancing Asthma Control and Growth: A Collaborative Effort

The study emphasizes the importance of close monitoring of growth in children receiving ICS for asthma. Healthcare providers should work closely with families to tailor treatment plans, taking into account individual factors that could influence growth.

Dr. Camel's Conclusion

This study is like a camel caravan carefully navigating a delicate desert ecosystem, seeking to balance the needs of asthma control and child growth. It shows that low-to-medium doses of ICS, administered through a valved holding chamber, are generally safe for preschool children with asthma, but close monitoring is crucial for identifying potential growth-related concerns.